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Emergent research in the past decades has brought to light the importance of lymphatic vessels in tissue
homeostasis, immunity, metabolism, and inflammation. InNature, Klotz et al. (2015) demonstrate that cardiac
lymphatics have a unique ontology compared to visceral lymphatics and that promoting their growth can
improve cardiac function following injury.Studies in the 18th and 20th centuries
established the existence of an extensive
lymphatic network in the mammalian
heart and charted its anatomy and
drainage pathways (Miller, 2011). Despite
this knowledge, together with the fact
that interference with lymphatic drainage
predisposes to the development of
edema, infection, inflammation, and
tissue fibrosis, the ontogeny and func-
tions of cardiac lymphatic vessels in
(patho)physiologic processes have been
neglected.
In a recent study, Klotz and colleagues
evaluated the embryonic origin of cardiac
lymphatic vessels. Whether or not more
than one source of lymphatic endothelial
progenitor cells exists in the embryo has
been a long-debated topic. In re-visiting
this question, several recent publications,
including that of Klotz and colleagues,
have identified sources of progenitor cells
in addition to the venous-derived pool
that contribute to generation of lymphatic
vasculature in a tissue-specific manner
(Klotz et al., 2015; Martinez-Corral et al.,
2015; Stanczuk et al., 2015). Klotz et al.
mapped the development of cardiac
lymphatic vessels from mid-embryo-
genesis (E12.5) to P15, noting that the
first obvious lymphatic endothelial cellsdid not sprout from pre-existing coronary
vessels, but migrated in from extra-car-
diac sources (Figure 1). Lineage tracing
studies using Tie2Cre and PdgfbCreERT2
mouse lines, both of which label endo-
thelial cells, showed that up to 20%
of cardiac lymphatic endothelial cells
derive from non-endothelial progenitor
cell sources. Lineage tracing using
markers of established sources of
cardiac progenitor cells—the pro-epicar-
dial organ (Wt1CreERT2), cardiac meso-
derm (Mesp1Cre, Nkx2-5Cre), or cardiac
neural crest (Wnt1Cre)—demonstrated
that none of these lineages were found
to generate lymphatic vascular endothe-
lial cell progeny.
Hemogenic endothelium refers to a
specialized population of endothelial cells
giving rise to hemopoietic stem/progeni-
tor cells. To investigate whether cardiac
lymphatic endothelial cells derive from
hemogenic endothelium during embryo-
genesis, lineage tracing using Vav1Cre,
PdgfrbCre, and Csf1rCreERT2 lines was
undertaken and documented a contribu-
tion to the generation of cardiac lymphatic
vessels, though with various degrees of
magnitude; PdgfrbCre labeled cardiac
lymphatic endothelial cells with highest
efficiency (28% at E17.5), followedby Vav1Cre (14%) and Csf1rCreERT2
(< 5%). Possible reasons underlying vari-
ations in labeling include the inducible
nature of the Csf1rCreERT2 line (induced
with one pulse of 4-hydroxytamoxifen
at E7.5), compared to constitutive
PdgfrbCre and Vav1Cre lines, and the
degree of restriction of expression of
each of these genes in hemogenic versus
other endothelial/hemopoietic compart-
ments. Nonetheless, studies in which
Prox1 was deleted in Tie2+ and Vav1+
compartments provided additional evi-
dence for a dual endothelial and hemo-
genic endothelial progenitor cell origin of
cardiac lymphatic vessels (Figure 1).
Deletion of Prox1 using Tie2Cre resulted
in virtual absence of cardiac lymphatic
vessels during embryogenesis, coupled
with dysmorphic hearts. Whether defec-
tive heart morphology was a result of the
absence of lymphatic vessels, or due to
a role for Prox1 in endocardial cells was
not conclusively established, though
formation of the ventricular septa and
cardiac valves appeared normal in mutant
mice. Various degrees of severity of
disruption to the cardiac lymphatic
vessels were observed in embryonic
Tie2CreProx1flox/flox mice, and an essen-
tially normal coverage of lymphatic
Figure 1. Embryonic Development of Cardiac Lymphatics and Their Response to Injury in Adult Heart
A schematic diagram of lymphatic vascular development from embryonic to adult stages, depicting the emergence of lymphatic vessels (green) beginning
at embryonic day 12.5 (E12.5), is shown. By adulthood, lymphatics cover the majority of the epicardium of the heart. In embryonic hearts, lymphatic vessels
originate from both endothelial Tie2+ and Tie2 progenitors. Lineage tracing studies performed by Klotz and colleagues attribute this previously unrecognized,
non-venous source of lymphatic endothelial cells (LECs) as having a hemogenic endothelial origin. In the adult heart, myocardial infarction induces the growth of
cardiac lymphatics (red), a process further augmented by VEGF-C administration. This lymphangiogenic response following injury results in improved cardiac
function.
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at P7, suggesting postnatal recovery of
the cardiac lymphatic phenotype. It is
unclear whether a hemogenic endothelial
progenitor contribution to the cardiac
lymphatics was responsible for this re-
covery, or whether the deletion of Prox1
in the Tie2+ compartment in such cases
was incomplete. The lymphatic pheno-
type of mice in which Prox1 was deleted
using Vav1Crewas less severe, but none-
theless apparent during embryogenesis.
Interestingly, a second recently published
study identified c-Kit-positive but not
Vav-positive hemogenic endothelium as
a source of progenitor cells contributing
to the mesenteric lymphatic vasculature
(Stanczuk et al., 2015).
The authors next investigated cardiac
lymphatic vessel responses to ischemic
injury in an adult setting; myocardial
infarction (MI) was accompanied by
cardiac lymphangiogenesis, evidenced
by the increase in vascular endothelial
growth factor-3 (VEGFR-3), Prox-1 and
lymphatic endothelial LYVE-1 expression,
lymphatic branching and sprouting, and
significant increase in lymphatic number
from 24 hr up to 21 days post-MI. These
findings are in line with observations in
human ischemic hearts (Kholova´ et al.,
2011). To address the possible role of
lymphangiogenesis in heart function after
MI in mice, the authors promoted expan-
sion of lymphatic vessels in the heart by
treating Vegfr3lacZ/+ reporter mice withthe lymphangiogenic factor, VEGF-C;
indeed, augmenting lymphangiogenesis
significantly improves cardiac function,
as determined by smaller ventricular
end-systolic volumes and increased
ejection fraction, suggesting that stimu-
lation of lymphatic vessel growth may be
useful for cardiac repair following injury
(Figure 1). However, the mechanisms
whereby lymphangiogenesis improves
cardiac function in their model remain to
be defined, as do the effects of VEGF-C
treatment on the angiogenic response
of blood vessels, which also express
VEGFR3. MI is associated with inflamma-
tory and immune reactions. Recent pre-
clinical studies in models of inflammatory
skin and joint diseases demonstrated that
strategies to promote lymphangiogenesis
at the inflamed sites significantly reduced
tissue edema and immune cell infiltration
(Kim et al., 2014). By analogy, lymphan-
giogenesis observed after MI may thus
be a productive attempt to resolve inflam-
mation by supporting the clearance of
fluid, immune cells, and inflammatory
mediators from the injured heart. Several
experimental studies in large animals
have shown that interference with cardiac
lymph flow after injury resulted in tissue
fluid stasis, predisposition to infection,
inflammation, and fibrosis in the hearts
(Cui, 2010; Miller, 2011). Obstruction of
cardiac flow can also induce similar
changes in coronary arteries that may
promote development of atherosclerosisCell Metabol(Lemole, 1981). Conversely, the persis-
tence of lymphatic vessels may over
time sustain local immune reactions by
supporting transport of immune cells
and antigens, which in some circum-
stances may lead to tertiary lymphoid
organ formation and transplant rejec-
tion (Ruddle, 2014). In fact, targeting
lymphatic vessel activation can reduce
alloimmune reactions in cardiac allografts
(Nyka¨nen et al., 2010). Therefore, addi-
tional insights are needed to justify pro-
moting lymphangiogenesis as a therapeu-
tic target in cardiac associated diseases.
Future studies to define the origin and
identity of cardiac lymphatic endothelial
cells and mechanisms of cardiac
lymphatic vessel growth during develop-
ment and pathology, and to investigate
the potential for therapeutic modulation,
are warranted.
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Replenishing the lost or dysfunctional insulin-producing b cell mass in diabetic patients could slow down or
reverse disease progression. Kondegowda et al. (2015) now show that osteoprotegerin and denosumab, in-
hibitors of the receptor activator of the NF-kB Ligand (RANKL) pathway and osteoclast activation, stimulate
human b cell proliferation and therefore possess therapeutic potential.Type 1 and type 2 diabetes (T1D and T2D)
result from autoimmune destruction or
loss of functional b cell mass, respec-
tively. Daily insulin injections or current
pharmacological treatment do not fully
substitute for b cell loss to prevent uncon-
trolled hyperglycemia and the devastating
secondary complications associated with
both forms of diabetes. The Joslin
Medalist Study demonstrated that even
after 50 years of insulin-dependent dia-
betes, b cells persist and are functional
(Keenan et al., 2010). Hence, strategies
that trigger endogenous b cell replication
or regeneration have great therapeutic
value.
Despite the slow turnover of b cells, b
cell mass can be expanded upon meta-
bolic demand during pregnancy by the
action of lactogenic hormones (Rieck
and Kaestner, 2010). Osteoprotegerin
(OPG) is upregulated in pregnant mice
(Rieck et al., 2009), a finding confirmed
in the study of Kondegowda et al. pub-
lished in Cell Metabolism. Additionally,
OPG was upregulated in other mouse
models associated with increased b cell
expansion, pointing at OPG as universal
mediator of b cell proliferation (Rieck
et al., 2009). OPG acts as soluble decoy
receptor and binds to RANKL and TNF-related apoptosis-inducing ligand (TRAIL)
receptors RANK and death receptor (DR),
respectively, to block their binding (Walsh
and Choi, 2014) (Figure 1). The FDA-
approved drug and humanized mono-
clonal antibody denosumab (DMB) binds
to human RANKL and inhibits RANK re-
ceptor interaction similarly to OPG. Inhibi-
tion of RANK receptor blocks osteoclast
differentiation and promotes bone forma-
tion for osteoporosis therapy (Miller,
2009). Kondegowda et al. show that
OPG and DMB stimulate human b cell
proliferation, raising the possibility that
DMB might be repurposed for b cell
regeneration.
Kondegowda et al. showed OPG upre-
gulation in pancreatic islets of transgenic
mice overexpressing placental lactogen
in b cells compared to normal mice.
They successively identified OPG as
pivotal mediator of lactogen-driven b cell
proliferation. Long-term OPG treatment
caused significant increase in b cell prolif-
eration and mass in young mice, and
induced b cell proliferation in old mice.
OPG injections rescued streptozotocin-
induced b cell ablation, resulting in
reduced diabetes incidence. OPG also
triggered elevated b cell replication in hu-
man islet cells without causing dedifferen-tiation, as measured by PCR analysis
of genes relevant to b cell function.
Glycogen synthase kinase-3 (GSK3b)
and CREB, two factors involved in b cell
proliferation (Dalle et al., 2011; Wang
et al., 2015), were regulated upon OPG
stimulation in rodent and in human islets.
A competition assay in human islet cells
proved that OPG interferes with RANKL/
RANK interaction, thus repressing its
downstream signaling. Thus, RANK sig-
naling puts a brake on b cell proliferation,
which was confirmed in vitro in islets
from the RANK lox animals. Finally, hu-
man islets transplanted under the kidney
capsule of euglycemic immunodeficient
mice exhibited increase b cell proliferation
upon a single injection of DMB, indicating
that the drug acts as a b cell proliferative
trigger in a humanized mouse model.
These pre-clinical results provide
important new clues on lactogenic hor-
mone and RANK signaling in human b
cell proliferation and hold promise for
future clinical use. However, before this
can be achieved we need to understand
how these signaling pathways mechanis-
tically act together to enhance b cell
proliferation. The lactogenic hormones
prolactin (PRL) and placental lactogen
(PL) are elevated during pregnancy
